Effectiveness of 5-Pyrrolidone-2-Carboxylic Acid and Copper Sulphate (Pirometaxine) in Cold Dry Air Induced Rhinitis With or Without Viral Superinfection
DOI:
https://doi.org/10.17140/PRRMOJ-2-115Keywords:
5-Pyrrolidone-2-carboxylic acid, Copper sulphate, Pirometaxine, Cold dry air induced rhinitis, Viral rhinitis, Common coldAbstract
Introduction:Exposure to cold dry air can determine rhinitis-like symptoms. 5-Pyrrolidone-2-Carboxylic acid (PCA) and Copper Sulphate (CS) showed antiviral and osmoprotectant ef-fect. Aim of this study is evaluation of effectiveness of 5-Pyrrolidone-2-Carboxylic acid (PCA) and Copper Sulphate pentahydrate (CS) (Pirometaxine) association in the treatment of cold dry air rhinitis with or without viral infection.Methods:Fifty consecutive adult patients affected by cold dry air rhinitis with or without viral/bacterial infection were enrolled in this prospective observational study and treated with pyro-glutamic acid (PCA) plus copper sulphate (CS) (pirometaxine). All patients underwent an ob-jective evaluation with optic fiber endoscopy and symptoms assessment at time of enrolment, after 3 and 7 days of treatment. Results:All symptoms scores decreased at 3 and 7 days with a mean Total Symptoms Score of 5.98±2.22 and 1.30±1.23, respectively. Twenty-seven patients (54%) reached a Total Symp-toms Score of zero after 7 days. Median number of days until healing was 6. Only 18% of cases had turbinate hypertrophy and 10% nasal mucosa hyperaemia after 7 days. Main side effects were nasal itch in 4 cases (8%) and nasal burning in one case (2%).Conclusions: The association of 5-Pyrrolidone-2-carboxylic acid and copper sulphate (piro-metaxine) represent a safe treatment for CDA-induced rhinitis with or without viral infection, with few side effects. Clinical importance of this therapy will be better understood with further studies, comparing results to those observed in a control group.
References
Fendrick AM. Viral respiratory infections due to rhinoviruses: current knowledge, new developments. Am J Ther. 2003; 10(3): 193-202.
Heikkinen T, Jarvinen A. The common cold. Lancet. 2003; 361(9351): 51-59.
Winther B, Gwaltney JM, Mygind N, Tuner RB, Hendely JO. Site of rhinovirus recovery after point inoculation of the upper airway. JAMA. 1986; 256(13): 1763-1767.
Van Gerven L, Boeckxstaens G, Hellings P. Up-date on neuro-immune mechanisms involved in allergic and non-allergic rhini-tis. Rhinology. 2012; 50(3): 227-235. doi: 10.4193/Rhino11.152
Braat JP, Mulder PG, Fokkens WJ, van Wijk RG, Rijntyes E. Intranasal cold dry air is superior to histamine challenge in determining the presence and degree of nasal hyperreactivity in nonallergic noninfectious perennial rhinitis. Am J Respir Crit Care Med. 1998; 157(6 Pt 1): 1748-1755. doi: 10.1164/ajrc-cm.157.6.9701016
Togias AG, Proud D, Linchtenstein LM, et al. The osmolality of nasal secretions increases when inflammatory mediators are released in response to inhalation of cold, dry air. Am Rev Respir Dis. 1988; 137(3): 625-629. doi: 10.1164/ajrccm/137.3.625
Rennie P, Bowtell P, Hull D, Charbonneau D, Lamkin-Wil-liams R, Oxford J. Low pH gel intranasal sprays inactivate influ-enza viruses in vitro and protect ferrets against influenza infec-tion. Respir Res. 2007; 8: 38. doi: 10.1186/1465-9921-8-38
Giranda VL, Heinz BA, Oliveira MA, et al. Acid-induced structural changes in human rhinovirus 14: possible role in un-coating. Proc Natl Acad Sci USA. 1992; 89(21): 10213-10217.
Borkow G, Gabbay J. Putting copper into action: copper-impregnated products with potent biocidal activities. FASEB J. 2004; 18(14): 1728-1730. doi: 10.1096/fj.04-2029fje
Biagi M, Giachetti D, Miraldi E, Figura N. New non-al-coholic formulation for hand disinfection. J Chemother. 2014; 26(2): 86-91. doi: 10.1179/1973947813Y.0000000111
Adam P, Stiffman M, Blake RL. A clinical trial of hypertonic saline nasal spray in subjects with the common cold or rhinosi-nusitis. Arch Fam Med. 1998; 7(1): 39-43.
Togias A. Non-allergic rhinitis. In: Mygind N, Naclerio R, Durham S, eds. Rhinitis. Marcel Dekker Inc, New York; 1998: 383-399.
Diemer F, Sanico A, Horowitz E, Togias A. Non-allergenic inhalant triggers in seasonal and perennial allergic rhinitis. J. Al-lergy Clin. Immunol. 1999; 103: S2.
Kauffmann F, Neukirch F, Annesi I, Korobaeff M, Dore MF, Lellouch J. Relation of perceived nasal and bronchial hyperre-sponsiveness to FEV1, basophil counts, and methacholine re-sponse. Thorax. 1988; 43(6): 456-461.
Jankowski R, Philip G, Togias AG, Naclerio RM. Demon-stration of bilateral cholinergic secretory response after unilater-al nasal cold, dry air challenge. Rhinology. 1993; 31(3): 97-100.
Philip G, Jankowski R, Baroody F, Naclerio RM, Togias AG. Reflex activation of nasal secretion by unilateral inhalation of cold dry air. Am Rev Respir Dis. 1993; 148(6 Pt 1): 1616-1622. doi: 10.1164/ajrccm/148.6_Pt_1.1616
Slome D. Physiology of nasal circulation. Lect Sci Basis Med. 1955-1956; 5: 451-468.
Cruz AA, Naclerio RM, Proud D, Togias A. Epithelial shed-ding is associated with nasal reactions to cold, dry air. J Al-lergy Clin Immunol. 2006; 117(6): 1351-1358. doi: 10.1016/j. jaci.2006.01.054
Cole P, Forsyth R, Haight JS. Effects of cold air and exercise on nasal patency. Ann Otol Rhinol Laryngol. 1983; 92(2 Pt 1): 196-198. doi: 10.1177/000348948309200220
Cruz AA, Togias AG, Lichtenstein LM, Kagey-Sobotka A, Proud D, Naclerio RM. Local application of atropine attenuates the upper airway reaction to cold, dry air. Am Rev Respir Dis. 1992; 146(2): 340-346. doi: 10.1164/ajrccm/146.2.340V
Togias A, Proud D, Kagey-Sobotka A, Norman P, Lichten-stein L, Naclerio R. The effect of a topical tricyclic antihista-mine on the response of the nasal mucosa to challenge with cold, dry air and histamine. J Allergy Clin Immunol. 1987; 79(4): 599- 604.
Cruz AA, Togias AG, Lichtenstein LM, Kagey-Sobotka A, Proud D, Naclerio RM. Steroid-induced reduction of histamine release does not alter the clinical nasal response to cold, dry air. Am Rev Respir Dis. 1991; 143(4 Pt 1): 761-765. doi: 10.1164/ ajrccm/143.4_Pt_1.761
Airaudo CB, Gaytesorbier A, Armand P. Stability of Gluta-mine and Pyroglutamic Acid under Model System Conditions: Influence of Physical and Technological Factors. J. Food Sci. 1987; 52: 1750-1752. doi: 10.1111/j.1365-2621.1987.tb05926.x
Turner RB, Hendley JO. Virucidal hand treatments for pre-vention of rhinovirus infection. J Antimicrob Chemother. 2005; 56(5): 805-807. doi: 10.1093/jac/dki329V
Kumar A, Bachhawat AK. Pyroglutamic acid: throwing light on a lightly studied metabolite. Current Science. 2012; 102(2): 288-297.
Bleackley MR, Macgillivray RT. Transition metal homeosta-sis: from yeast to human disease. Biometals. 2011; 24(5): 785- 809. doi: 10.1007/s10534-011-9451-4
Grass G, Rensing C, Solioz M. Metallic Copper as an Anti-microbial Surface. Appl Environ Microbiol. 2011; 77(5): 1541- 1547.
Biagi M. In vitro synergistic effect of 5-pyrrolidone-2-car-boxylic acid (PCA) and copper sulphate pentahydrate (CS) against Staphylococcus aureus and Staphylococcus epidermidis. Household and Personal Care. 2011; 4: 10-12.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Pulmonary Research and Respiratory Medicine (PRRM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
